In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price.
On March 11, 2024, the White House released President Biden's FY 2025 Department of Health and Human Services (HHS) Budget in Brief, which outlines $130.7 billion in discretionary.
Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, discusses the dynamic landscape of the biosimilars market, providing key insights into its current status and future projections.
Prescription drug costs have skyrocketed and become a growing financial burden, but the White House’s drug price controls will not solve the drug affordability crisis. However, they will threaten the development of future cures and harm patient health.